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MOST drugs targeted to the respiratory tract are used for
their local action. For example, ephidrine for nasal
decongestion, beta-2 agonists for bronchodilatation, and
inhaled steroids to suppress the inflammation seen in
asthmatic airways. Since the drug is delivered directly to
its required site, only a small quantity is needed for an
adequate therapeutic response, and consequently there is
a low incidence of systemic side effects compared with
oral or intravenous administration. More recently, it has
become apparent that the lining of the respiratory tract,
from nasal mucosa to airways and alveoli, may be used
for the absorption of a drug for its systemic effect. This
route of administration maybe particularly attractive if it
avoids the metabolic destruction encountered when
some drugs are administered by alternative routes (for
instance, peptides and proteins are rapidly destroyed by
peptidaseswhenOvenby the oral route). Ifthere is a lack
ofclinical response to an aerosolized drug, it is important
to question whether the drug has failed or whether deliv-
ery to the site ofaction is inadequate. To deliver therapeu-
tic agents by inhalation to the lower respiratory tract,
inhaled drug particles must have appropriate aerody-
namic characteristics. In addition, the anatomy and
pathophysiology of the patient’s respiratory tract, mode
of inhalation through the inhaler, and the characteristics
of the inhalational device itself, may significantly affect
drug deposition.
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The Importance of Aerosol Particle Size
The aerodynamic size of a particle is a
measurement that takes into account the diameter
and density of a particle, and is the most important
factor determining the site of drug deposition in
the lung. Drug particle size has been shown to be
clinically important (for example, a bronchodilator
administered in an aerosol of small particles
(1.8m diameter) results in more effective
bronchodilatation than when given in an aerosol of
larger particles).
The amount of drug reaching the site of action
usually dictates the therapeutic affect. Thus, meas-
urement of particle size without reference to the
amount of drug (mass) contained in the particles
likely to reach the lungs can be misleading. For
example, an aerosol of a drug solution, containing
1000 1 btm particles and ten 10m particles sounds
ideal for drug delivery. However, a 10 l.tm particle
contains the same mass of drug as the 1000 1 l.tm
particles. Thus, as the 10 l.tm particles are likely
to be filtered at the nose, only a small amount of
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drug is likely to reach the lung. If an aerosol of
ultra fine particles is used, it needs to be much
more concentrated or inhaled over a much longer
period of time to deliver an equivalent mass of
drug. This is very difficult in practice and an aerosol
of 2-3 l.tm diameter particles is considered
most practical for penetration into the lung and
delivery of a sufficient mass of drug to the site of
action.
Care needs to be taken before the introduction of
new aerosol formulations or drug delivery devices, to
ensure that the medication has the best chance of
reaching the airways. For example, steroids for
nebulization are in a suspension. Individual,
micronized, steroid particles of 2 l.tm diameter ac-
quire a coating of the carrier solution during
nebulization, resulting in a larger droplet. Thus, a
nebulizer chamber with a baffle system that only
allows particles of 2 t.tm or less to leave the chamber,
will release virtually no steroid particles for inhala-
tion. The ideal nebulizer must release droplets large
enough to contain steroid particles, but small enough
to reach the intrathoracic airways.
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Anatomy and Physiology
The nose: The ability of the nose to act as a filter is
enhanced by its narrow slit-like passages and the
turbulent flow of air in it. In adults, few particles
larger than 10 t.tm (e.g. pollen grains) are able to
penetrate the nose during breathing at rest, while
most particles smaller than 2 }.tm (e.g. mould spores)
by-pass the nose. Inhaled particles trapped by the
nasal filter are cleared from the nose within 30 min
by mucociliary clearance, and swallowed.
The majority of young children nose breathe at
rest, and may inhale nebulized aerosols nasally when
given by face mask. Nasal breathing results in lower
lung deposition of aerosolized drug in adults, but
little is known about this in infants. The absence of
nasal hair in young children and the fact that the
infant’s head is larger with respect to its body than
in adulthood may make nasal breathing less of a
problem in infants than might be expected.
The lungs: As young children breathe tidally when
given aerosolized medication, this may reduce depo-
sition of drug in the lung peripheries, compared with
older, more compliant patients, who inhale deeply
and slowly. If their airways become narrowed by
mucus, inflammation or obstruction, the linear veloc-
ity of air increases further, enhancing impaction and
more central deposition of drug.
After deposition: Several factors can affect drug ab-
sorption and clearance from the respiratory tract
following deposition. The mucociliary transport sys-
tem, which covers the airways down to the terminal
bronchioles, may decrease absorption. Either parti-
cles are trapped in mucus and transported to the
oropharynx, or drug transport is affected by binding
to mucus compounds. Absorption from the lung
epithelium extending from the ciliated cells of the
airways is also important. Aerosolized drug adminis-
tered to the respiratory tract usually needs to cross
the epithelial barrier to enter lung tissue for a topical
effect, or the circulation for a systemic effect. Al-
though pulmonary epithelium has a high resistance
to movement of water and compounds that are not
lipid-soluble, diffusion of poorly lipid-soluble com-
pounds is often more rapid than expected, suggest-
ing aqueous pores may aid pulmonary epithelial
diffusion. Certain drugs such as sodium cromo-
glycate are known to undergo carrier-mediated trans-
port. Enhancement of drug uptake by altered
paracellular or transcellular (vesicular) transport is an
exciting new area of research.
Drug Delivery Devices
Unfortunately, many aerosolized drugs are mar-
keted and trials undertaken with little information
available to the clinician on drug output from various
drug delivery devices. Such information is essential
to optimize the therapeutic effect, and to avoid mis-
interpretation of results from clinical trials. The fol-
lowing examples of drug delivery, via inhalers with
spacer device attachments and by nebulization, illus-
trate how basic information on the delivery method
used can profoundly affect the dose of drug deliv-
ered to the patient.
Metered dose inhalers and spacer devices: Metered
dose inhalers (MDI) cannot be recommended for use
alone to deliver aerosols to children because of
problems with co-ordination. Successful drug deliv-
ery from a metered dose inhaler requires co-ordina-
tion of actuation and inhalation, as the dose is best
released at the beginning of a slow deep inspiration.
The aerosol cloud they deliver contains micronized
drug suspended in propellants and surfactant. Drop-
let size is 20-40 l.tm at the MDI orifice and the speed
is approximately 30 m/s, decreasing to 3-4 m/s
within a few centimetres. Droplet size decreases
rapidly due to propellent evaporation. Of the parti-
cles delivered directly from a MDI, 80-90% cannot
follow the inspired air stream and strike the
oropharynx.
Spacer devices provide a reservoir of aerosol from
which the child can inhale, with no need to co-
ordinate inspiration and MDI actuation. Within the
spacer device, the velocity of aerosol particles is
reduced and surrounding propellants evaporate,
leading to reduction in particle size. Drug delivery to
the lung is equal to, or better than, when an MDI is
used alone, and oropharangeal deposition of drug is
markedly reduced. For instance, only 0.7 mg of a 5
mg dose of sodium cromoglycate is available for
inhalation after actuation into a 750 ml spacer, yet
slightly more drug is available from the spacer in
particles likely to reach the lower airways. In the case
of inhaled steroids, use of a large volume spacer has
been shown to decrease suppression of the
hypothalamic-pituitary-adrenal axis. 3,4
The method of use and physical characteristics of
the spacer may have profound effects on the amount
of drug delivered.
Multiple actuations of drug into a spacer prior to
inhalation should be avoided as drug output per
actuation is considerably reduced. For example, if
five actuations of a beclomethasone dipropionate
MDI (250 btg/actuation, becloforte) are placed into a
spacer and then inspired, the dose to patient is the
same as if one actuation was placed into the spacer
and inhaled.
Drug should be inhaled immediately following
actuation, as up to 50% of drug available for inhala-
tion may deposit on the spacer walls within 10 s.
Using certain drugs, such as sodium cromoglycate
(5 mg/actuation), twice as much drug is available for
inhalation when a large volume spacer is used, as
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opposed to popular small volume spacers.
When generated, aerosols are usually highly
charged. By coating the walls of polycarbonate
spacer devices with an antistatic lining, which re-
duces electrostatic attraction, drug output may be
considerably increased.
Nebulized drug delivery: Only 10% of the inhaled
dose reaches the lower airways in adults. The
amount young children and infants inhale is un-
known. The following examples illustrate the impor-
tance of a basic knowledge of nebulizer drug deliv-
ery.
The amount of nebulized drug available for inha-
lation, including that deposited in the nose and
upper airways, may be independent of the child’s age
after 6 months of age. Adults and older children
inspire aerosol from the nebulizer, and, as their
inspiratory flow and volume is large, they also en-
train surrounding air. The younger the child, the less
room air is entrained, and the more concentrated the
aerosol they inspire. Although the total dose of
aerosol inhaled per breath in young children and
adults may be similar, dose per kilogram of body
weight will be much greater in infancy. It has been
suggested that, on the basis of these findings, aero-
sols should be administered in a weight-corrected
basis for children aged more than 6 months of age.
A closely fitting face mask increases drug delivery,
as a mask held just a couple of centimetres away from
the face may result in a marked decrease (up to 85%)
in drug inspired.
Increasing the flow of gas through the nebulizer
from 4 to 8 1/min alters the rate of drug output, the
gas volume in which it is distributed, the aerosol
concentration, and the volume of aerosol available
during the inspiratory phase. The amount of drug
contained in particles smaller than 5 t.tm (respirable
particles) increases considerably with higher flows.
Clinical examples: Inhalation of drug aerosols has
been popularized by the immense success in asthma
treatment. Many other drugs are now given in aero-
sol form, for example:
Sputum viscosity is markedly enhanced in patients
with cystic fibrosis due to DNA released from
leukocytes and other cells. An enzyme DNase is now
available that, when given by nebulization, markedly
reduces sputum viscosity by splicing DNA strands.
Nebulized pentamidine has been successfully used
as prophylaxis againstpneumocystis carinii infection
in patients with human immunodeficiency virus in-
fection. Work on deposition is continuing as recur-
rence of pneumocystis at the lung apex has been
recorded.
Nebulized Edmonston-Zagreb strain vaccine re-
suited in an 86% seroconversion in a group of 5-
month-old children, protecting against measles. In
younger children, administration of the vaccine by
aerosol has the theoretical advantage that antibodies
lining the respiratory epithelium, predominantly IgA,
are less likely to be acquired from the mother and to
inhibit viral replication, than circulating maternally
derived antibodies which are predominantly IgG.
References
1. Clay MM, Pavier D, Newman SP, Clarke SW. Factors influencing the size distribu-
tion of aerosol from jet nebulisers. Thorax 1983; 38: 755-759.
2. O’Callaghan C, Lynch J, Cant M, Robertson C. Improvement in sodium
cromoglycate delivery from spacer device by of antistatic lining, imme-
diate inhalation, and avoiding multiple actuations of drug. Thorax 1993; 48:
603-606.
3. Brown PH, Blundell G, Greening AP. Do large volume spacer devices reduce the
systemic of high dose inhaled cortico-steroids? Thorax 1990; 45: 736-739.
4. Prahl P, Gents D. Decreased adreno-cortical suppression utilising nebuhaler for
inhalation of steroid aerosols. Clin Allergy 1987; 17: 393-398.
5. O’Callaghan C, Cant M, Robertson C. Delivery of beclomethasone diproprionate
from spacer device. What dose is available for inhalation? Thorax 1994; 49:
961-964.
6. Collis GG, Cole CH, Le Souef PN. Dilution of nebulised aerosols by air entrainment
in children. Lancet 1990; 336: 341-343.
7. Everard ML, Clarke AR, Milner AD. Drug delivery from jet nebulisers. Arch Dis
Child 1992; 67." 586-591.
8. Shak S, Capon DJ, Hellmiss R, Masters SA, Baker CL. Recombinant human DNase
reduces the viscosity of cystic fibrosis sputum. Proc NatlAcad Sci USA 1990; 87."
9188-9192.
9. Shanley DJ, Luyckz BA, Haggerty MF, Murphy TF. Spontaneous pneumothorax in
AIDS patients with recurrent pneumocystic carinii pneumonia despite aerosolised
pentamadine prophylaxis. Chest 1991; 99: 502-504.
10. Sabin AB, Flores AA, De Castro F. Successful immunisation of infants with and
without maternal antibody by aerosolised measles vaccine. JAMA 1983; 249:
2651-2662.
Mediators of Inflammation. Vo13 (Supplement). 1994 S33